Else Nutrition (TSXV:BABY) Up 20% This Week on Major News

Else Nutrition

Followers of RichTV Live should be familiar with Else Nutrition Holdings Inc. (TSXV:BABY) (OTCPK:BABYF). It was one of Rich’s big winners last month and it’s a company with an incredible position in a lucrative market.

This week, BABY’s been on a tear, adding 20% value in just a few days. From its position at $0.51 on Monday, it’s now trading at $0.62—and its products have yet to hit shelves in the US or Canada. This means investors have a lot to look forward to.

“This is one of the companies that I’m really, really excited about,” says Rich. “I love companies that are going to save the world, that see a problem and have a solution. I think Else Nutrition has that kind of potential.”

Else Nutrition Receives Patent for US Adult Market

The reason for BABY’s recent jump is, in part, due to its big news yesterday.

Else Nutrition received a notice of allowance from the US Patent & Trademark Office to extend its existing patents to cover the adult market for malnutrition. This applies to Else’s proprietary formula for adults who have specific malnutrition-related conditions.

These conditions include lean body mass and declining basal metabolic rates.

Enter Your E-mail Address To Subscribe

* indicates required
 

To address those issues, the company’s patented composition provides necessary proteins, amino acids, and other required nutrients, all in a single food serving.

CEO and Co-Founder of Else Nutrition, Hamutal Yitzhak, considers this notice of allowance a “milestone” for the company:

“It paves the way for future, already planned, product expansion beyond the baby and toddler market segments. Furthermore, the growth of our intellectual property portfolio in the US is timely as we get set to launch our products there this year.”

 “This is the kind of news that could make a stock like this skyrocket,” says Rich. “I think everybody needs to put BABY on alert today.”

The company already expects its infant formula to be ready for market in Q2 of this year. With the extension of its existing patent, Else can expect to fast-track the process of delivering its adult formula to consumers in need.

As Yitzhak further explains:

“Our 100% plant-based formulation has functional and meaningful applications to a wide range of potential consumer markets. While we remain laser-focused on the launch of our baby products, our IP can also help serve the rapidly growing $5 billion U.S. plant-based food market giving those in need, nutritious clean label offerings.”

What Sets Else Nutrition Apart

Only three primary ingredients make up Else’s patented formula. These ingredients are tapioca and two whole plants—almonds and buckwheat—in their natural forms.

On top of that, it’s also made using a clean, chemical-free process. This means the formula is free of GMOs, pesticides, hormones, antibiotics, gluten, and phytoestrogens.

Last month, the company’s toddler formula ingredients received a favorable regulatory assessment from EAS Consulting Group, LLC. EAS offers global expertise in regulatory approvals with a specialty in FDA requirements.

This indicates that Else Nutrition should expect no barrier to entering the US market.

As the vast majority of infant formulas are milk-based or soy-based, Else’s 100% plant-based formula exists in its own market vertical. For health-conscious parents, it also represents the best option in the infant formula market, which is expected to be worth US103.75 billion by 2026.

What are your thoughts? If you think BABY is a good play, let us know about it! And keep watching RichTV Live for more updates from this and other exciting companies.

Featured image: DepositPhotos © AlikeYou

Please See Disclaimer

If You Liked This Article Click To Share


Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, Else Nutrition Holdings Inc. Bitrics Markets Group Inc. and/or Iman Consulting Group has or expects to receive $800 Canadian dollars from Market Jar Media Inc. for the creation and distribution of the video.

3) Statements and opinions expressed are the opinions of the author and not Bitrics Markets Group Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Bitrics Markets Group Inc. for this Article. Bitrics Markets Group Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Bitrics Markets Group Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Bitrics Markets Group Inc. relies upon the authors to accurately provide this information and Bitrics Markets Group Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Bitrics Markets Group Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Bitrics Markets Group Inc. does not render general or specific investment advice and the information on richtvlive.com should not be considered a recommendation to buy or sell any security. Bitrics Markets Group Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

5) Bitrics Markets Group Inc. and its owners, members, officers, directors, partners and consultants may own shares of the profiled companies, which it may sell at any time, including as soon as it deposits such shares into its trading accounts, during our campaign of the profiled companies stock, after our campaign or at any other time. We also may buy and sell securities in the profiled companies which may cause (a) decline in the price of the profiled companies stock due to our selling activities, (b) increased volatility due to our buying and selling of the profiled companies stock and (c) permit us to make substantial profits while we are profiling each of these companies, yet may result in a diminished value to the stock for investors. for any company mentioned in the Article.